secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0001104659-25-025338
Event type: other_material
Sentiment:  positive
Materiality: 0.78
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond grants Servier worldwide license for BDTX-4933; $70M upfront, up to $710M milestones
--------------------------------------------------------------------------------

- Upfront payment of $70M; eligible for up to $710M in development/commercial milestones plus tiered royalties on global sales.
- Servier will lead global development and commercialization of BDTX-4933 in RAF/RAS-mutant solid tumors, including NSCLC.
- BDTX-4933 is a Phase 1 small molecule designed to target RAS mutations and RAF alterations with best-in-class potential.
- Black Diamond continues to advance its MasterKey platform; deal provides non-dilutive capital to support pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465925025338/0001104659-25-025338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465925025338/tm259476d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-025338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer